Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Rong Fan, George Papatheodoridis, Jian Sun, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 6, pp. 1368-1378
Open Access | Times Cited: 255

Showing 1-25 of 255 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Jian Zhou, Hui‐Chuan Sun, Zheng Wang, et al.
Liver Cancer (2023) Vol. 12, Iss. 5, pp. 405-444
Open Access | Times Cited: 191
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
Hong You, Fu‐Sheng Wang, Taisheng Li, et al.
Journal of Clinical and Translational Hepatology (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 95
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights
Diyang Xie, Kai Zhu, Zhenggang Ren, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 2, pp. 216-228
Open Access | Times Cited: 90
The ALBI score: From liver function in patients with HCC to a general measure of liver function
Hidenori Toyoda, Philip J. Johnson
JHEP Reports (2022) Vol. 4, Iss. 10, pp. 100557-100557
Open Access | Times Cited: 88
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jie-Yi Shi, Jian Zhou, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 2, pp. 206-216
Open Access | Times Cited: 79
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis
Ian Lockart, Malcolm Guan Hin Yeo, Behzad Hajarizadeh, et al.
Hepatology (2022) Vol. 76, Iss. 1, pp. 139-154
Open Access | Times Cited: 78
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 62
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 29
EASL position paper on clinical follow-up after HCV cure
Thomas Reiberger, Sabela Lens, Giuseppe Cabibbo, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 326-344
Closed Access | Times Cited: 24
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
Mario Romeo, Marcello Dallio, Carmine Napolitano, et al.
Diagnostics (2025) Vol. 15, Iss. 3, pp. 252-252
Open Access | Times Cited: 2
HCC surveillance after SVR in patients with F3/F4 fibrosis
George N. Ioannou
Journal of Hepatology (2020) Vol. 74, Iss. 2, pp. 458-465
Open Access | Times Cited: 135
Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients
Guosheng Yuan, Yangda Song, Qi Li, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 68
Burden of liver cancer: From epidemiology to prevention
Qianru Li, Maomao Cao, Lin Lei, et al.
Chinese Journal of Cancer Research (2022) Vol. 34, Iss. 3, pp. 554-566
Open Access | Times Cited: 65
Risk stratification and early detection biomarkers for precision HCC screening
Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, et al.
Hepatology (2022), pp. n/a-n/a
Open Access | Times Cited: 60
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B
Dong Ji, Yan Chen, Jingfeng Bi, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1515-1524
Open Access | Times Cited: 42
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis
Pierre Nahon, Jessica Bamba‐Funck, Richard Layese, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 584-595
Open Access | Times Cited: 42
Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma
Xiaohua Xing, Linsheng Cai, Jiahe Ouyang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 38
Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review
Endrit Shahini, Giuseppe Pasculli, Antonio Giovanni Solimando, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4286-4286
Open Access | Times Cited: 29
Screening of liver cancer with abbreviated MRI
Maxime Ronot, Pierre Nahon, Jordi Rimola
Hepatology (2023) Vol. 78, Iss. 2, pp. 670-686
Closed Access | Times Cited: 23
Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions
Hamish Innes, Pierre Nahon
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1332-1337
Open Access | Times Cited: 23
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis
Hashem B. El–Serag, Fasiha Kanwal, Jing Ning, et al.
Gut (2024) Vol. 73, Iss. 6, pp. 1000-1007
Closed Access | Times Cited: 15
Integration of artificial intelligence in clinical laboratory medicine: Advancements and challenges
Heying Xie, Yin Jia, Shanrong Liu
Deleted Journal (2024) Vol. 2, Iss. 3
Open Access | Times Cited: 9
Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: Prospective study
Gamal Shiha, Ayman Hassan, Nasser Mousa, et al.
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top